BeOne Medicines Ltd. has issued its Notice of 2026 Annual General Meeting of Shareholders, setting the session for 3:30 p.m. local time on 11 June 2026 at the offices of Homburger AG, Prime Tower, Hardstrasse 201, Zürich. Shareholders recorded at 12:00 p.m. CEST on 22 May 2026 will be entitled to vote. The company’s ordinary shares trade on Nasdaq (ticker: ONC), the Hong Kong Stock Exchange (code: 06160) and the STAR Market of the Shanghai Stock Exchange (code: 688235).

Key agenda items

1. Financial reporting and loss appropriation • Approval of audited Swiss statutory standalone and consolidated financial statements for FY 2025. • Approval of the appropriation of the accumulated loss for FY 2025. • Discharge of the Board of Directors and Executive Management Team for activities during FY 2025.

2. Board composition • Re-election of seven current directors and election of three new directors (Dr. Felix J. Baker, Ms. Elizabeth F. Mooney and Dr. Charles L. Sawyers) for terms ending at the 2027 AGM. • Re-election of John V. Oyler as Chairman through the 2027 AGM. • Re-election/election of Dr. Margaret Dugan and Ms. Elizabeth F. Mooney to the Compensation Committee.

3. Auditor matters • Ratification of Ernst & Young LLP, Ernst & Young and Ernst & Young Hua Ming LLP as independent auditors and re-election of Ernst & Young AG as statutory auditor for FY 2026. • Authorization for the Board to set auditor compensation.

4. Compensation resolutions (Swiss law and advisory votes) • Advisory approval of 2025 compensation for Named Executive Officers. • Approval of maximum aggregate Board compensation and Executive Management Team compensation for FY 2027. • Advisory approval of the Swiss Statutory Compensation Report and Non-Financial Matters Report for FY 2025.

5. Equity incentive plans • Amendment and restatement of the 2016 Share Option and Incentive Plan, including a consultant sub-limit. • Amendment and restatement of the 2018 Employee Share Purchase Plan.

6. Share capital mandates • General mandate to issue, allot or deal with unissued shares and/or ADSs up to 20 % of issued share capital (excluding treasury shares) until the next AGM. • Mandate to repurchase up to 10 % of issued ordinary shares (excluding RMB shares and treasury shares) until the next AGM. • Authorization, for up to five years on a rolling basis, for allocation of shares to Amgen Inc. to maintain its ownership percentage following issuances under the general mandate.

7. Procedural items • Election of Schweiger Advokatur/Notariat, Zug, as Independent Voting Representative through the 2027 AGM. • Authorization to adjourn the AGM if additional proxy solicitation is required.

Proxy material distribution and voting

• From 28 April 2026, proxy materials and the 2025 Annual Report will be available online at the company’s investor relations website and relevant regulatory platforms in the U.S., Hong Kong and Shanghai. • Holders of Swiss-registered and HKEx-listed ordinary shares, and ADS holders, will receive a Notice of Internet Availability; printed materials will be mailed only upon request or where legally required. • RMB share investors on the STAR Market will receive printed materials by mail. • Proxy/voting instruction deadlines: – Ordinary share and HK register holders: 9 June 2026, 3:30 p.m. CEST (9:30 a.m. EDT / 9:30 p.m. HKT). – ADS holders: 3 June 2026, 10:00 a.m. EDT. – STAR Market investors: voting via SSE trading system or internet platform on 11 June 2026 during designated Beijing-time windows.

The Board of Directors unanimously recommends that shareholders vote in favor of all proposed resolutions.